SAN DIEGO, Oct. 11, 2016 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Dr.
Laurent Peyrin-Biroulet will present
etrasimod S1P receptor profile data at the United European
Gastroenterology Week (UEGW) Meeting on Tuesday, October 18 at 6:15am ET. The meeting is taking place
October 15-19 in Vienna, Austria. The data will also be
published in the December issue of United European
Gastroenterology Journal, a peer-reviewed medical journal
providing coverage of both translational as well as clinical
studies from all fields of gastroenterology.
The following abstract will be presented:
Lecture: LB20 - RECEPTOR PROFILE AND EFFICACY OF ETRASIMOD
(APD334), AN ORAL, NEXT-GENERATION SPHINGOSINE-1-PHOSPHATE RECEPTOR
MODULATOR IN DEVELOPMENT FOR ULCERATIVE COLITIS
Session: 807 - Improving therapy in IBD
Session Type: Late Breaking Abstracts
Date: Tuesday, October 18, 2016
About Arena Pharmaceuticals
We are a biopharmaceutical
company focused on developing novel, small molecule drugs across a
range of therapeutic areas. We have three primary proprietary
investigational clinical programs: etrasimod (APD334) in Phase 2
evaluation for ulcerative colitis, APD371 entering Phase 2
evaluation for the treatment of pain associated with Crohn's
disease, and ralinepag (APD811) in Phase 2 evaluation for pulmonary
arterial hypertension (PAH). Additionally, we have
collaborations with the following pharmaceutical companies: Eisai
Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences Ltd.
(Phase 2 candidate), and Boehringer Ingelheim International GmbH
(preclinical candidate).
Our US operations are located in San
Diego, California. Our primary clinical operations are
located in Zug, Switzerland, and
our commercial manufacturing for BELVIQ is located in Zofingen,
Switzerland.
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements about the upcoming presentation; the publication of the
data; and Arena's focus, primary programs and collaborations. For
such statements, Arena claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results
may differ materially from Arena's expectations. Factors that could
cause actual results to differ materially from the forward-looking
statements include those disclosed in Arena's filings with the
Securities and Exchange Commission. These forward-looking
statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Contact: Arena Pharmaceuticals, Inc.
Kevin R. Lind, Chief Financial
Officer
klind@arenapharm.com
858.453.7200, ext. 1716
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-announces-acceptance-of-late-breaking-etrasimod-abstract-at-the-united-european-gastroenterology-week-uegw-meeting-300342129.html
SOURCE Arena Pharmaceuticals, Inc.